Dow Jones Industrial Average Futures Signal Strong Start After Presidential Debate

Does This Biotech Really Have 360% Upside?

by Josh Selway

Published on Oct 10, 2016 at 9:10 AM

Dow Jones Industrial Average (DJIA) futures are signaling a positive open this morning, following a disappointing opening week for the fourth quarter. Traders are digesting last night's U.S. presidential debate, which many believe kept the odds in favor of Democratic nominee Hillary Clinton. Stocks are also looking to feed off of rising oil prices, with November-dated crude futures trading 0.9% higher at $50.28 per barrel -- although questions remain surrounding an agreement among top oil producers to curb output. 

Continue reading for more on today's market, including: 

US Stock Futures October 10

Futures on the Dow Jones Industrial Average (DJIA) are almost 63 points above fair value. 

5 Things You Need to Know Today
  1. The People's Bank of China (PBOC) move that boosted Chinese stocks. 
  2. The Chicago Board Options Exchange (CBOE) saw 634,927 call contracts traded on Friday, compared to 434,574 put contracts. The resultant single-session equity put/call ratio declined to 0.68, while the 21-day moving average stayed at 0.65.
  3. Drug company Mylan NV (NASDAQ:MYL) has been getting pounded in the wake of the company's EpiPen controversy. Since their August peak north of $50, the shares have shed 28%, as analysts continue to slash their expectations. This morning, though, the stock is eyeing a major turnaround, adding 12% in electronic trading following news that MYL reached a $465 million settlement with the Department of Justice. 
  4. Dow stock United Technologies Corporation (NYSE:UTX) is down 1.5% in pre-market trading, on pace to breach the recently supportive $100 level, after a downgrade to "neutral" at Citigroup. The shares fell on Friday, too, hurt by rival Honeywell International Inc.'s (NYSE:HON) disappointing outlook. As of Friday's close, UTX has lost 8.4% since its annual high of $109.83 on Aug. 15. 
  5. TESARO Inc (NASDAQ:TSRO) is eyeing a 15% surge when the market opens, thanks to more positive news for its ovarian cancer drug, niraparib. This time around, the company reported the experimental drug improved the outcomes for all patients in its latest clinical study. A number of brokerage firms have since weighed in, including BofA-Merrill Lynch, which upgraded TSRO to "buy" from "neutral." 

buzz stocks Oct 10

Earnings and Economic Data

There are no economic reports on today's slate, but Chicago Federal Reserve President Charles Evans will speak. There are also no notable earnings reports for the day. To see what else is coming up on this week's schedule, click here

Don't miss the market's next move! Sign up now for Schaeffer's Midday Market Check

A Schaeffer's exclusive

6 Sectors for Summer

Access your FREE insider report before it's too late!



NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories

3 Million to Lose Jobs – and Not Because of Coronavirus?
A terrifying new trend can make you a millionaire or destroy your financial future.
Wall Street Reclaims Two Key Trendlines This Week
U.S.-China tensions and dire economic data still weigh, though
Dell Stock Jumps on Upbeat First Quarter
DELL announced an upbeat first-quarter report
Research Exposes Shortcut to Stock Market Wins
A simple way to stop picking losers, and start cashing in like Wall Street's elite.